AI Verdict
HIT has stronger fundamentals based on our AI analysis.
HIT vs HHS Fundamental Comparison
| Metric | HIT | HHS |
|---|---|---|
| Revenue | $33.3M | $159.6M |
| Net Income | $1.3M | $-811,000.0 |
| Net Margin | 3.8% | -0.5% |
| ROE | 7.5% | -4.0% |
| ROA | 5.5% | -0.9% |
| Current Ratio | 3.13x | 1.54x |
| Debt/Equity | 0.00x | 0.00x |
| EPS | $0.02 | $-0.11 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
HIT vs HHS: Frequently Asked Questions
Is HIT or HHS a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), HIT has stronger fundamentals. HIT is rated SELL (72% confidence) while HHS is rated STRONG SELL (88% confidence). This is not investment advice.
How does HIT compare to HHS fundamentally?
Health In Tech, Inc. has ROE of 7.5% vs HARTE HANKS INC's -4.0%. Net margins are 3.8% vs -0.5% respectively.
Which stock pays higher dividends, HIT or HHS?
HIT has a dividend yield of N/A or no dividend while HHS has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in HIT or HHS for long term?
For long-term investing, consider that HIT has SELL rating with 72% confidence, while HHS has STRONG SELL rating with 88% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about HIT vs HHS?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For HIT vs HHS, the AI consensus favors HIT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.